- Home
- CTMX vs APLT Comparison
CTMX vs APLT Comparison
Compare CTMX & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTMX
- APLT
- Stock Information
- Founded
- CTMX 2008
- APLT 2016
- Country
- CTMX United States
- APLT United States
- Employees
- CTMX N/A
- APLT N/A
- Industry
- CTMX Biotechnology: Pharmaceutical Preparations
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- CTMX Health Care
- APLT Health Care
- Exchange
- CTMX Nasdaq
- APLT Nasdaq
- Market Cap
- CTMX 444.3M
- APLT 44.0M
- IPO Year
- CTMX 2015
- APLT 2019
- Fundamental
- Price
- CTMX $2.39
- APLT $0.46
- Analyst Decision
- CTMX Strong Buy
- APLT Buy
- Analyst Count
- CTMX 2
- APLT 7
- Target Price
- CTMX $5.00
- APLT $6.10
- AVG Volume (30 Days)
- CTMX 2.0M
- APLT 2.7M
- Earning Date
- CTMX 08-07-2025
- APLT 08-06-2025
- Dividend Yield
- CTMX N/A
- APLT N/A
- EPS Growth
- CTMX 128.27
- APLT N/A
- EPS
- CTMX 0.49
- APLT N/A
- Revenue
- CTMX $147,557,000.00
- APLT $265,000.00
- Revenue This Year
- CTMX N/A
- APLT $415.60
- Revenue Next Year
- CTMX N/A
- APLT $1,323.96
- P/E Ratio
- CTMX $4.91
- APLT N/A
- Revenue Growth
- CTMX 23.81
- APLT N/A
- 52 Week Low
- CTMX $0.40
- APLT $0.30
- 52 Week High
- CTMX $3.10
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- CTMX 51.40
- APLT 65.27
- Support Level
- CTMX $2.36
- APLT $0.34
- Resistance Level
- CTMX $2.79
- APLT $0.36
- Average True Range (ATR)
- CTMX 0.15
- APLT 0.04
- MACD
- CTMX -0.02
- APLT 0.01
- Stochastic Oscillator
- CTMX 36.72
- APLT 91.01
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.